An enormous body of preclinical literature supports the therapeutic potential of inhibitors targeting G9A/GLP (EHMT2/EHMT1) in cancer and in a variety of other disease contexts, including inflammatory conditions and neurodegenerative disorders. Here, EHMT2 is linked to cancer.